
ALLO Stock Forecast & Price Target
ALLO Analyst Ratings
Bulls say
Allogene Therapeutics is a clinical stage immuno-oncology company with a positive outlook from a financial analyst, driven by their promising pipeline and recent addition of a new cohort to the ALPHA3 study which aims to provide important context for MRD-negative patients. The bull case scenario values the company at $11 per share using a DCF-based valuation methodology and an 85% probability of approval for their LBCL treatment. However, potential risks include shorter-than-expected effectiveness, safety concerns, and manufacturing challenges.
Bears say
Allogene Therapeutics is facing significant obstacles in their development of allogeneic T cell product candidates, as evidenced by a recent real-world study highlighting the unmet need in LBCL and a low proportion of patients receiving CART therapy in the 2L and 3L settings. Additionally, while some data on their ALLO-329 program will be released in 4Q26, there is still a lack of clinical and translation updates on this program, indicating potential hurdles in its development. Lastly, the company's financials may also be a cause for concern, as they have a heavy reliance on partnerships for their key pipeline and are facing competition from next-generation CAR T therapies.
This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ALLO Analyst Forecast & Price Prediction
Start investing in ALLO
Order type
Buy in
Order amount
Est. shares
0 shares